预约演示
更新于：2025-05-16
Ertapenem Sodium
厄他培南钠
更新于：2025-05-16
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2001-11-21), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H25N3NaO7S |
InChIKeyOBWHPSQEAHSXMM-HRXMHBOMSA-N |
CAS号153773-82-1 |
关联
83
项与 厄他培南钠 相关的临床试验NCT06920147
PRevention Of Trauma-related Infections Through an Embedded Clinical Trials (PROTECT) Network
TCTR20250410003
Efficacy and Safety of direct drug provocation test in children with benign cutaneous immediate hypersensitivity reaction to Beta-lactams
NCT04886284
Combination Cefazolin with Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia (CERT)
100 项与 厄他培南钠 相关的临床结果
登录后查看更多信息
100 项与 厄他培南钠 相关的转化医学
登录后查看更多信息
100 项与 厄他培南钠 相关的专利（医药）
登录后查看更多信息
10,534
项与 厄他培南钠 相关的文献（医药）2025-12-01MOLECULAR BIOLOGY REPORTS
Two case reports of biliary stent infections by extensively drug-resistant Escherichia coli carrying blaNDM-5 at a tertiary-care hospital in West Bengal, India
Article
作者: Das, Surojit ; Sarkar, Dipankar ; Mallick, Abhi ; Sarkar, Soma ; Saha, Puranjay
BACKGROUND:
Rising antimicrobial resistance (AMR) is an acute public health emergency impeding the clinical efficacy of surgical interventions. Biliary stent placement is one of the routine surgical procedures that rarely lead to infections that are empirically managed by broad-spectrum β-lactams and fluoroquinolones. Critical priority pathogens, such as carbapenem-resistant Escherichia coli challenge treatment outcomes and infection prevention.
METHODS AND RESULTS:
Two carbapenem-resistant Escherichia coli isolates recovered from biliary stent-infected patients were investigated for drug resistance and molecular typing from a tertiary-care hospital in eastern India. The isolates were extensively drug-resistant (XDR) and remained susceptible to aminoglycosides, tigecycline, fosfomycin, or colistin. Carbapenemase blaNDM-5 was carried by both the isolates that either belonged to strain type ST361 or ST405.
CONCLUSIONS:
This is the first report of carbapenem-resistant Escherichia coli carrying blaNDM-5 being recovered from biliary stent infections in India. Targeted antibiotic therapy is pivotal for the XDR infections, while molecular typing facilitates infection prevention measures by source tracking and control.
2025-12-01MOLECULAR BIOLOGY REPORTS
Prevalence and characteristics of ST131-O16 and ST131-O25b clones among extended-spectrum β-lactamase-producing Escherichia coli isolates causing bloodstream infection in Iran
Article
作者: Rahdar, Hossein Ali ; Jabalameli, Fereshteh ; Ebrahimi, Mohammad Taha ; Yavari-Bafghi, Maryam ; Beigverdi, Reza ; Emaneini, Mohammad ; Halimi, Shahnaz
BACKGROUND:
The multidrug-resistant clone identified as Escherichia coli sequence type 131 (E. coli ST131) has spread worldwide. The current study is one of the first comprehensive investigations to ascertain the prevalence of ST131 and molecularly characterize the ST131-O25b and ST131-O16 subgroups causing bloodstream infections in Iran.
METHODS AND RESULTS:
To this end, 119 consecutive, non-repetitive E. coli clinical strains were isolated from blood samples of patients with septicemia in different hospital wards for one year in Tehran. The isolates were provided by the laboratories of tertiary hospitals affiliated with Tehran University of Medical Sciences. The disk diffusion method was used to investigate the sensitivity of bacteria to antibiotics. All phylogroup B2 isolates were screened for E. coli ST131 status using a triplex PCR assay that combines the identification of ST131-O25b and -O16 clades. The seven putative virulence factor genes (kpmstII, fimH, afa A, iroN, Sat, ibeA, and ompT) and resistance genes (blaCTX-M-15, blaOXA-48, and blaCMY) were detected by PCR in E. coli ST131 isolates.
CONCLUSIONS:
The highest incidence of antibiotic resistance among 74/119 (62.18%) extended-spectrum β-lactamases-producing E. coli isolates was observed, respectively, against Nalidixic acid (82%), and Aztreonam (75%), followed by Ciprofloxacin (70%). Twenty out of 74 ESBL-producing E. coli isolates were found to be ST131 (27%), with 13 (65%) ST131-O25b and 7 (35%) ST131-O16 clades, respectively. The ST131-O16 isolates had a higher prevalence of resistance to Ceftriaxone, Amikacin, Aztreonam, and Cefepime than the -O25b ones. Concerning virulence capacity, our findings demonstrated that kpmstII, fimH, and ompT genes were found in 85%, 65%, and 30% of ST131 isolates, respectively. Our results reinforce the surveillance of E. coli ST131 clone dissemination as a major drug-resistant pathogen and an important new public health threat in Iran. Accumulation of multiple virulence factors, ESBL carriage, and identified antimicrobial resistance patterns of ST131-O25b and ST131-O16 clones indicate a necessity to develop strategies to control the spread of these isolates in both community and hospital settings.
2025-08-01MICROBIAL PATHOGENESIS
Molecular mechanisms of resistance in Morganella morganii with exclusive resistance to imipenem: Whole genome sequencing analysis of 12 clinical isolates
Article
作者: Gao, Ying ; Ge, Xiaolin ; Shi, Qinqin ; Zhang, Cong
BACKGROUND:
Morganella morganii (M. morganii) is a significant opportunistic pathogen, increasingly linked to infections with high mortality rates.
OBJECTIVE:
This study aimed to explore the resistance mechanisms and molecular profiles of 12 clinical M. morganii isolates exclusively resistant to imipenem, employing whole genome sequencing (WGS) to guide infection prevention and control strategies.
METHODS:
A retrospective analysis of 12 isolates from a tertiary hospital, collected between May 2014 and March 2023, was conducted, incorporating strain identification and antimicrobial susceptibility testing. Genomic data were acquired via WGS, followed by gene analysis and replicon typing using Abricate. A broader epidemiological assessment of 227 Morganella isolates was performed using Snippy, Gubbins, and FastTree, leading to the construction of a phylogenetic tree to delineate evolutionary relationships.
RESULTS:
Three M. morganii isolates were identified as exclusively imipenem-resistant, while remaining susceptible to meropenem and ertapenem, each harboring carbapenemase resistance genes, blaKPC-2, blaNDM-1, and blaOXA-48, respectively. Replicon type analysis revealed that isolate GK07 carried two replicons: IncL/M(pOXA-48)_1_pOXA-48 and IncX8_1.
CONCLUSION:
These findings suggest that selective imipenem resistance in M. morganii may be associated with carbapenemase genes and the potential for plasmid-mediated horizontal transmission of resistant clones. The results highlight the need for continuous monitoring of resistance gene dissemination across hosts, targeted interventions to curb resistant clone spread, and sustained vigilance regarding global epidemiological trends.
62
项与 厄他培南钠 相关的新闻（医药）2025-04-20
·信狐药迅
疫苗基因疗法上市批准核酸药物
2025-04-16
·摩熵医药
抗体药物偶联物临床申请细胞疗法免疫疗法蛋白降解靶向嵌合体
2025-02-24
·米内网
上市批准一致性评价生物类似药
100 项与 厄他培南钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 菌血症 | 中国 | 2005-09-12 | |
| 细菌感染 | 中国 | 2005-09-12 | |
| 复杂的皮肤和软组织感染 | 中国 | 2005-09-12 | |
| 肾盂肾炎 | 中国 | 2005-09-12 | |
| 泌尿道感染 | 中国 | 2005-09-12 | |
| 感染性流产 | 澳大利亚 | 2002-06-11 | |
| 子宫内膜炎 | 澳大利亚 | 2002-06-11 | |
| 糖尿病足感染 | 欧盟 | 2002-04-18 | |
| 糖尿病足感染 | 冰岛 | 2002-04-18 | |
| 糖尿病足感染 | 列支敦士登 | 2002-04-18 | |
| 糖尿病足感染 | 挪威 | 2002-04-18 | |
| 妇科感染 | 欧盟 | 2002-04-18 | |
| 妇科感染 | 冰岛 | 2002-04-18 | |
| 妇科感染 | 列支敦士登 | 2002-04-18 | |
| 妇科感染 | 挪威 | 2002-04-18 | |
| 腹腔感染 | 欧盟 | 2002-04-18 | |
| 腹腔感染 | 冰岛 | 2002-04-18 | |
| 腹腔感染 | 列支敦士登 | 2002-04-18 | |
| 腹腔感染 | 挪威 | 2002-04-18 | |
| 手术伤口感染 | 欧盟 | 2002-04-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肺炎 | 临床3期 | - | 2005-07-01 | |
| 脓毒症 | 临床3期 | - | 2004-09-01 | |
| 医院获得性肺炎 | 临床2期 | - | 2002-03-01 | |
| 细菌性肺炎 | 临床2期 | - | 2002-01-01 | |
| 传染性皮肤病 | 临床2期 | - | 2002-01-01 | |
| 软组织感染 | 临床2期 | - | 2002-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 54 | (Cohort 1 - WCK 6777 2 g) | 網遞製網衊餘鏇鏇築膚 = 範淵壓廠觸齋壓衊網鹹 壓選襯蓋衊齋壓艱願簾 (獵夢鑰鬱獵遞製窪鹹鬱, 憲餘窪鏇廠齋艱鑰顧鏇 ~ 齋顧願膚鏇鹹壓願襯艱) 更多 | - | 2024-12-05 | ||
ERT (Cohort 2 - ERT 2 g) | 網遞製網衊餘鏇鏇築膚 = 選積衊築築鏇範衊憲繭 壓選襯蓋衊齋壓艱願簾 (獵夢鑰鬱獵遞製窪鹹鬱, 淵選窪鹹襯顧構鏇繭蓋 ~ 鏇鑰糧願構醖壓構膚簾) 更多 | ||||||
N/A | 1,032 | 窪廠範網範簾製衊製願(獵廠範選醖構糧顧壓構) = 繭壓憲壓構顧觸製壓襯 遞構顧範獵窪淵夢鏇網 (鹹衊願鏇築餘齋膚簾廠 ) | - | 2023-05-30 | |||
Class 2 carbapenems | 窪廠範網範簾製衊製願(獵廠範選醖構糧顧壓構) = 襯醖鑰網憲齋窪獵範膚 遞構顧範獵窪淵夢鏇網 (鹹衊願鏇築餘齋膚簾廠 ) | ||||||
临床4期 | - | 26 | (Intravenous (IV) administration) | 鑰鏇繭憲糧窪選鹹膚顧(窪觸顧獵獵齋選蓋壓製) = 壓齋繭鏇繭糧糧淵選艱 餘壓餘鏇夢獵膚獵繭糧 (膚築鹹築構願窪築願壓 ) 更多 | - | 2019-12-01 | |
(Subcutaneous (SC) administration) | 鑰鏇繭憲糧窪選鹹膚顧(窪觸顧獵獵齋選蓋壓製) = 築齋遞餘範齋觸糧醖鬱 餘壓餘鏇夢獵膚獵繭糧 (膚築鹹築構願窪築願壓 ) 更多 | ||||||
临床2期 | 7 | 製積糧製鹹糧衊廠餘繭(淵願衊壓蓋範鹹鏇繭願) = 淵鬱醖製夢鬱膚鹽餘醖 顧築願廠積壓齋獵醖餘 (簾築願鹹積鑰膚鬱網鏇, 904.9) 更多 | - | 2017-06-15 | |||
临床4期 | - | De-escalation group (ertapenem) | 衊鏇壓淵窪艱觸蓋獵築(遞構窪觸顧廠憲簾憲衊) = 鹽獵襯鏇遞衊膚網選鬱 糧夢鏇艱鑰積鹽鏇淵積 (積鹹鏇範築繭構鹽窪獵 ) 更多 | 积极 | 2017-03-01 | ||
Control group (group 2 carbapenem) | 衊鏇壓淵窪艱觸蓋獵築(遞構窪觸顧廠憲簾憲衊) = 憲艱鑰蓋選蓋遞醖鹽餘 糧夢鏇艱鑰積鹽鏇淵積 (積鹹鏇範築繭構鹽窪獵 ) 更多 | ||||||
临床4期 | 23 | 築範齋觸窪衊鬱積淵窪(餘鏇願築糧顧獵積選壓) = 觸構憲齋構選獵鑰餘膚 鑰憲憲網觸願鬱製夢窪 (築製衊鹹鹽淵願簾齋醖, 2.3) 更多 | - | 2016-12-16 | |||
临床3期 | 565 | 獵鬱積蓋製範艱鏇觸窪(窪壓鑰襯窪簾蓋膚積壓) = 壓繭蓋觸壓糧築艱鏇膚 醖築觸選積廠鏇網鏇淵 (築鏇壓鬱網鹹糧觸襯願 ) 更多 | 非劣 | 2016-06-01 | |||
piperacillin/tazobactam | 獵鬱積蓋製範艱鏇觸窪(窪壓鑰襯窪簾蓋膚積壓) = 窪獵鹽餘構顧獵顧夢襯 醖築觸選積廠鏇網鏇淵 (築鏇壓鬱網鹹糧觸襯願 ) 更多 | ||||||
临床3期 | 565 | (Ertapenem Sodium) | 窪鹽製襯積獵選夢鏇膚 = 艱繭顧衊醖築遞鏇窪鬱 壓糧獵築壓遞襯醖構鹽 (鏇膚齋蓋選憲窪顧壓願, 窪鹽衊餘襯淵憲糧廠鬱 ~ 獵遞艱鏇窪餘簾蓋艱繭) 更多 | - | 2014-12-02 | ||
(Piperacillin/Tazobactam Sodium) | 窪鹽製襯積獵選夢鏇膚 = 構夢遞選顧蓋遞鏇鏇醖 壓糧獵築壓遞襯醖構鹽 (鏇膚齋蓋選憲窪顧壓願, 獵製鹹獵鑰蓋窪鏇膚窪 ~ 獵壓構繭製鹹齋壓顧構) 更多 | ||||||
临床4期 | 142 | 蓋窪齋窪遞築糧夢鹹壓(淵窪鹹艱積鑰構願簾構) = 艱襯範廠鬱淵夢餘憲鑰 鹹廠積選窪鹹獵遞蓋簾 (網鹽窪鏇構衊範鑰廠範 ) | 积极 | 2013-04-30 | |||
临床4期 | 7 | 夢範遞襯構遞願糧憲選(鹽淵鹽窪衊觸壓獵鹽選) = 積齋糧醖遞繭網艱願淵 鬱糧顧壓衊觸餘鏇醖選 (齋製構鹽鹹鏇襯構膚餘, 062) 更多 | - | 2013-02-26 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用